FDA Nod For BCRX - Decision In Japan, Europe Next, ENLV Soars On COVID Trial Data, STRO Abuzz

RTT News

by Super Admin 64 Views

Today's Daily Dose brings you news about Johnson & Johnson submitting the first-ever drug for a mutation-specific lung cancer to the FDA, Sutro Biopharma's encouraging data from an ongoing dose-escalation phase I study of STRO-002 for patients with ovarian cancer, Enlivex' positive interim data of Allocetra in COVID-19 trial, and BioCryst's hereditary angioedema drug securing FDA nod.